GB2122084B - Anti-tumour micro-organism obtained products - Google Patents

Anti-tumour micro-organism obtained products

Info

Publication number
GB2122084B
GB2122084B GB08313054A GB8313054A GB2122084B GB 2122084 B GB2122084 B GB 2122084B GB 08313054 A GB08313054 A GB 08313054A GB 8313054 A GB8313054 A GB 8313054A GB 2122084 B GB2122084 B GB 2122084B
Authority
GB
United Kingdom
Prior art keywords
obtained products
organism obtained
tumour micro
disclosed
tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB08313054A
Other languages
English (en)
Other versions
GB2122084A (en
GB8313054D0 (en
Inventor
Edgar Ernst Ribi
John Leonard Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of GB8313054D0 publication Critical patent/GB8313054D0/en
Publication of GB2122084A publication Critical patent/GB2122084A/en
Application granted granted Critical
Publication of GB2122084B publication Critical patent/GB2122084B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB08313054A 1982-05-26 1983-05-12 Anti-tumour micro-organism obtained products Expired GB2122084B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/382,406 US4435386A (en) 1982-05-26 1982-05-26 Refined detoxified endotoxin product

Publications (3)

Publication Number Publication Date
GB8313054D0 GB8313054D0 (en) 1983-06-15
GB2122084A GB2122084A (en) 1984-01-11
GB2122084B true GB2122084B (en) 1986-02-05

Family

ID=23508812

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08313054A Expired GB2122084B (en) 1982-05-26 1983-05-12 Anti-tumour micro-organism obtained products

Country Status (7)

Country Link
US (1) US4435386A (enExample)
JP (1) JPS58222027A (enExample)
CA (1) CA1225591A (enExample)
DE (1) DE3318568C2 (enExample)
FR (1) FR2527444B1 (enExample)
GB (1) GB2122084B (enExample)
IT (1) IT1164244B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505899A (en) * 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
US4497730A (en) * 1984-04-03 1985-02-05 The United States Of America As Represented By The Department Of Health And Human Services Method for obtaining periplasmic proteins from bacterial cells using chloroform
NL8401226A (nl) * 1984-04-16 1985-11-18 Univ Utrecht Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie.
US4629722A (en) * 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4845036A (en) * 1987-02-03 1989-07-04 The United States Of America As Represented By The Department Of Health And Human Services Process for isolation of the B oligomer of pertussis toxin
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
WO1998035665A1 (fr) * 1997-02-14 1998-08-20 Ajinomoto Co., Inc. Antagonistes des endotoxines
WO2000058456A2 (en) 1999-03-30 2000-10-05 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
EP2283868B1 (en) 2002-07-15 2016-03-30 Board of Regents, The University of Texas System Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer
WO2008094183A2 (en) * 2006-07-11 2008-08-07 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US20120244185A1 (en) 2009-09-16 2012-09-27 Vaxart ,Inc. Immunization strategy to prevent h1n1 infection
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
HK1225631A1 (zh) 2013-09-19 2017-09-15 Novavax, Inc. 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
EA033248B1 (ru) 2014-02-20 2019-09-30 Вэксарт, Инк. Композиция и способ индукции иммунного ответа
JP6912394B2 (ja) 2015-06-12 2021-08-04 バクサート インコーポレイテッド Ｒｓｖおよびノロウイルス抗原の小腸送達のための製剤
AU2017225769B2 (en) 2016-03-02 2023-01-05 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
AU2017294751B2 (en) 2016-07-13 2023-10-05 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2

Also Published As

Publication number Publication date
JPS6234730B2 (enExample) 1987-07-28
DE3318568C2 (de) 1987-01-15
DE3318568A1 (de) 1984-01-12
IT1164244B (it) 1987-04-08
US4435386A (en) 1984-03-06
JPS58222027A (ja) 1983-12-23
GB2122084A (en) 1984-01-11
FR2527444A1 (fr) 1983-12-02
CA1225591A (en) 1987-08-18
FR2527444B1 (fr) 1987-02-20
GB8313054D0 (en) 1983-06-15
IT8321289A0 (it) 1983-05-25

Similar Documents

Publication Publication Date Title
GB2122084B (en) Anti-tumour micro-organism obtained products
GB2122083B (en) Anti-tumour micro-organism obtained products
SE8302774L (sv) Raffinerad, detoxifierad endotoxinprodukt samt sett att framstella detsamma jemte en terapeutisk komposition som innehaller produkten
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
GB8325500D0 (en) Electrothermal treatment of cancerous/tumorous tissue
WO1999004265A8 (en) Cancer associated nucleic acids and polypeptides
DE3361598D1 (en) Process for the preparation of polysaccharide-protein complexes from bacterial envelopes, products obtained and immunogenic compostions containing them
JPS6452800A (en) Cytokeratine tumor marker
CA2253632A1 (en) Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna
NZ209635A (en) Pharmaceutical composition containing extract from microorganism and detoxified endotoxin
GB2276623A (en) Cytotoxic drug therapy
AU551992B2 (en) Glycolipid extract derived from blood or organ homogenate for treatment of wounds
EP0031285A3 (en) Immuno-stimulating preparations based on ribosomal rna and process for the preparation of the rna
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
PT76272A (en) Process for preparing 20-amino tylosin derivatives
ZA905927B (en) Biological preparation and its use
DE2967143D1 (en) Diagnostic method, especially for the early recognition of malignant tumors and/or viral diseases, and means to carry it out
SE8304435D0 (sv) Forfarande for framstellning av en substans med karcinostatisk och immunostimulerande aktivitet
IT8121484A0 (it) Estratto da piante del genere epimedium, procedimento per lapreparazione di detto estratto, agente immunostimolante che comprende detto estratto come componente efficace e immunoterapia mediante l'impiego di detto estratto.
IT7828629A0 (it) Procedimento per migliorare le proprieta' fisiche di polimeri di fosfazeni.
PT74455A (en) Process for preparing novel substances having carcinostatic and immunostimulating activity and of a carcinostatic agent containing same
HU9301719D0 (en) Medical preparatives for treatment of b-cell tumours
SU619185A1 (ru) Способ лечени злокачественных опухолей органов малого таза
DE3772798D1 (en) Heat retaining apparatus for concast and worked semi-products
KR0177821B1 (en) Pharmaceutical compositions containing 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee